PeptideSearch

CJC-1295

Tested in people

Get notified when the evidence changes.

It has been tested in people, but it is not an approved medicine. The studies are usually small.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-06-12

Also called DAC:GRF / Modified GRF 1-29 / Tesamorelin analogue

A long-acting copy of the natural signal for growth hormone release, tested in small early studies in people. Not approved.

The basics

What is it?
A long-lasting lab-made copy of the brain signal that tells the body to release growth hormone.
What do we know?
Small early studies in people show it raises growth hormone for days after one dose.
What do we still not know?
Whether that leads to any real benefit, and what happens with repeated use over time.

Official status: Not nominated for 503A compounding · Checked 2026-06-12

Can a doctor prescribe this?

Small pharmacy (503A)
Never put forward to FDA
Large outsourcing facility (503B)
Never put forward to FDA

Not FDA approved and not on the 503A bulks list.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

Lab suppliers we list: 16

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

Spot an error? corrections@peptidesearch.org

We'll email you when a new study, trial or status change lands for CJC-1295. Unsubscribe in one click.